Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

Mitotech

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Mitotech CSO to Present at Mitochondria-Targeted Drug Development Summit

Details:

SkQ1 (visomitin), is a cardiolipin peroxidation inhibitor, designed to sustain and restore mitochondrial function and interrupt apoptosis in mitochondrial conditions like LHON, dry eye disease and glaucoma.

Lead Product(s): Visomitin

Therapeutic Area: Ophthalmology Product Name: SkQ1

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 24, 2022

ASK
US

Upload
your Pipeline Activity

Mitotech

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Mitotech Granted Orphan Drug Designation by FDA for Visomitin in LHON

Details:

USFDA has granted ODD for the company’s topical cardiolipin peroxidation inhibitor, SkQ1(Visomitin), for the treatment of Leber’s Hereditary Optic Neuropathy a rare inherited condition that can lead to blindness.

Lead Product(s): Visomitin

Therapeutic Area: Ophthalmology Product Name: SkQ1

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 15, 2021

ASK
US

Upload
your Pipeline Activity

Mitotech

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Mitotech and Essex Bio-Technology Complete Enrollment in VISTA-2 – a pivotal Phase 3 Clinical Study of SkQ1 for Dry Eye Disease

Details:

VISTA-2 is a multi-centre, randomized, double-blind, placebo-controlled clinical study involving two treatment arms: SkQ1 ophthalmic solution and vehicle solution, administered BID.

Lead Product(s): Visomitin

Therapeutic Area: Ophthalmology Product Name: SkQ1

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Essex Bio

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 25, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY